Business
PDS Provides Business Update & Full-Year Results
PDS Provides Business Update & Full-Year Results.
About this update from Emv Capital Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 8002G\n NetScientific PLC\n 31 March 2022\n \n \n \n \n NetScientific plc\n \n \n (\"NetScientific\" or the \"Group\") \n \n \n \n \n \n PDS \n Biotech Provides Business Update and Reports Fourth-Quarter and Full-Year 2021 Financial Results\n \n \n \n \n \n \n London, UK - 31 March 2022\n \n - NetScientific plc (AIM: NSCI), the international life sciences and sustainability technology investment and commercialisation Group, announces that its portfolio company, PDS Biotechnology Corporation (Nasdaq: PDSB), today provided a business update and announced its financial results for the year ended December 31, 2021.\n \n \n \n \n \n PDS Highlights for the Period\n \n \n · \n Achieved several milestones in the VERSATILE-002 Phase 2 combination trial of PDS0101-KEYTRUDA® (pembrolizumab) for recurrent and/or metastatic human papillomavirus (HPV)16-associated head and neck cancer. These milestones include:\n \n \n o \n Presented preliminary safety data on a total of 18 checkpoint inhibitor naïve patients at the 2022 Multidisciplinary Head and Neck Cancers Symposium. Highlights from the presentation include the absence of dose-limiting toxicities, drug discontinuation related to toxicity, or any significant immune-related adverse events. Subjects received a median of 4 doses of PDS0101 (range 1-5) and a median of 6 doses of KEYTRUDA® (range 1-13).\n \n \n o \n Achieved preliminary objective response benchmarks that enabled us to advance towards full enrolment of 54 patients in the checkpoint inhibitor naïve patient cohort.\n \n \n o \n Initiated enrolment in the checkpoint inhibitor-refractory cohort.\n \n \n · \n Announced initiation of an investigator-initiated trial with Mayo Clinic for patients with HPV-associated oropharyngeal cancer at high risk of recurrence. The trial will evaluate PDS0101 as monotherapy and in combination with KEYTRUDA®.\n \n \n · \n Announced encouraging preclinical data for the universal flu vaccine that demonstrated a potent neutralization response against multiple strains of the influenza virus and provided protection against infection after challenge with a live H1N1 pandemic strain of influenza in preclinical animal subjects.\n \n \n · \n Granted U.S. Patent Application by the United States Patent and Trademark Office fo...